Table 2.
Coronavirus disease 2019 therapies and outcomes
| Total | Newly diagnosed diabetes | Pre‐existing diabetes | P | |
|---|---|---|---|---|
| (n = 62) | (n = 19) | (n = 43) | ||
| Worst severity classification of COVID‐19, n (%) | ||||
| Critical | 19 (30.6) | 10 (52.6) | 9 (20.9) | 0.018 |
| Severe | 39 (62.9) | 9 (47.4) | 30 (69.8) | 0.153 |
| Moderate | 4 (6.5) | 0 (0) | 4 (9.3) | 0.303 |
| Outcomes, n (%) | ||||
| Death | 6 (9.6) | 2 (10.5) | 4 (9.3) | 1 |
| Discharged alive | 52 (83.9) | 16 (84.2) | 36 (83.7) | 1 |
| Transferred | 4 (6.5) | 1 (5.3) | 3 (7.0) | 1 |
| Worst route of oxygen delivery, n (%) | ||||
| No oxygen demand | 4 (6.5) | 0 (0.0) | 4 (9.3) | 0.303 |
| Nasal or mask | 26 (41.9) | 6 (31.6) | 20 (46.5) | 0.403 |
| High flow nasal cannula | 13 (21.0) | 3 (15.8) | 10 (23.3) | 0.737 |
| Non‐invasive positive pressure ventilation | 14 (22.6) | 9 (47.4) | 5 (11.6) | 0.006 |
| Invasive ventilation | 5 (8.1) | 1 (5.3) | 4 (9.3) | 1 |
| Glucocorticoids | ||||
| Methylprednisolone therapy | 32 (51.6) | 14 (73.7) | 18 (41.9) | 0.028 |
| Dexamethasone | 30 (48.4) | 5 (26.3) | 25 (58.1) | 0.028 |
| Others, n (%) | ||||
| Remdesivir | 53 (85.5) | 17 (89.5) | 36 (83.7) | 0.709 |
| Tocilizumab | 18 (29.0) | 10 (52.6) | 8 (18.6) | 0.013 |
| Baricitinib | 14 (22.6) | 4 (21.1) | 10 (23.3) | 1 |
| Heparin | 51 (82.3) | 18 (94.7) | 33 (76.7) | 0.149 |
Data are expressed as number and percentage.
COVID‐19, coronavirus 2019.